Monitor proxy vote outcome, a dissident victory would signal board dissatisfaction but is unlikely. Watch for definitive proxy materials and voting recommendations from ISS/Glass Lewis. Near-term stock price may be range-bound with low volume given OTC listing and lack of new operational catalysts.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 20 $0.6100entry
- T+1 · 6mo ago +11.48%α +11.28% · $0.6800
- T+5 · 6mo ago +8.20%α +6.39% · $0.6600
- T+20 · 5mo ago −9.67%α −10.41% · $0.5510
- T+60 · 3mo ago −10.90%α −15.91% · $0.5435
Price Chart
How similar events traded
Executive Summary
Vaxart filed additional definitive proxy soliciting materials in connection with its 2026 Annual Meeting scheduled for July 16, 2026. Management is urging employees and shareholders to vote for its slate of six director nominees, opposing a dissident group led by Daniel P. Houle that seeks to replace half the board. The outcome likely favors management given the dissidents' small ownership (~0.7%) and perceived lack of relevant experience.
Key Financial Metrics
Key Facts
- Annual Meeting scheduled for July 16, 2026.
- Dissident stockholder Daniel P. Houle nominated three director candidates to replace three of six board seats.
- Board unanimously recommends voting FOR its six nominees, citing dissidents' lack of biotech expertise.
- New director James B. Breitmeyer appointed on April 23, 2026, strengthening the board ahead of the contest.
- Management sent an employee communication emphasizing the importance of supporting the current board.
- Prior preliminary proxy (PREC14A) filed May 19, 2026 indicates a formal proxy fight.
Financial Impact
No financial figures disclosed; proxy contest costs and potential distraction are immaterial compared to market cap.
Risk Factors
- Dissident could win significant institutional support if shareholders are dissatisfied with performance.
- Proxy fight may distract management from clinical milestones and operations.
- Low liquidity on OTC market could amplify any price moves on vote outcome.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001213900-26-059237 |
| Document: 0001213900-26-059237-index-headers.html | 0001213900-26-059237 |
| Document: 0001213900-26-059237-index.html | 0001213900-26-059237 |
| Document: 0001213900-26-059237.txt | 0001213900-26-059237 |
Track record
23 reports on VXRT
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +37.66% at T+60 after the May 1, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.3700 Now $0.3600 +2.70% settles Feb 4
- Oct 19, 202628d ago 8-K Neutral 3/10 Entry $0.4900 Now $0.3600 −26.53% settles Jan 15
- Jul 28, 202615w ago 8-K Neutral 2/10 Entry $0.4800 to $0.4900 Now $0.3600 −25.00% ▲ +2.08% −2.53% vs SPY
- Jul 7, 202618w ago 8-K Neutral 4/10 Entry $0.5500 to $0.4500 Now $0.3600 −34.55% ▼ −18.18% −21.27% vs SPY
- Jul 6, 202619w ago DEFA14A Neutral 5/10 Entry $0.6200 to $0.4540 Now $0.3600 −41.94% ▼ −26.77% −28.93% vs SPY
- Jul 2, 202619w ago DEFA14A Bullish 5/10 Entry $0.6400 to $0.4500 Now $0.3600 −43.75% ▼ −29.69% −33.51% vs SPY
- Jul 2, 202619w ago 8-K Neutral 4/10 Entry $0.6400 to $0.4520 Now $0.3600 −43.75% ▼ −29.38% −32.80% vs SPY
- Jun 26, 202620w ago DEFA14A Neutral 4/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
- Jun 26, 202620w ago DEFA14A Neutral 3/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
- Jun 26, 202620w ago 8-K Mixed 5/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers